ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

Japan's Daiichi Sankyo to seek OK for omicron booster by April 2024

Shionogi and KM Biologics also eye homegrown shots targeting variants

Daiichi Sankyo's bivalent booster vaccine candidate contains a messenger RNA component of the original coronavirus strain and another of the BA.4 and BA.5 omicron subvariants.

TOKYO -- Japanese drugmaker Daiichi Sankyo aims to begin clinical trials of a vaccine booster candidate targeting the omicron variant of the coronavirus as soon as spring, hoping to file for authorization of the shot by April 2024.

A few domestic peers including KM Biologics and Shionogi also are racing to roll out homegrown omicron boosters. Japanese players trail U.S. rivals Pfizer and Moderna in creating bivalent boosters that offer protection against the omicron variant as well as the original virus strain.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more